Palvella Therapeutics PVLA Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's additional paid-in capital?
- Palvella Therapeutics (PVLA) reported additional paid-in capital of $383.42M in Q1 2026.
- How has Palvella Therapeutics's additional paid-in capital changed year-over-year?
- Palvella Therapeutics's additional paid-in capital increased by 143.5% year-over-year, from $157.49M to $383.42M.
- What is the long-term trend for Palvella Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Palvella Therapeutics's additional paid-in capital has grown at a -7.6% compound annual growth rate (CAGR), from $242.67M to $163.34M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.